Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
The Japanese group has seen potential in Audentes' manufacturing capabilities as well as its pipeline.
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
The Swiss group picks up Spark Therapeutics for $4.8bn, marking the biggest gene therapy buyout since Novartis’s $8.7bn move on Avexis.
As data on Amicus Therapeutics' clinical-stage Pompe disease candidate roll in, the group locks up preclinical gene therapy assets.
Companies that want to play in rare diseases need to shop for gene therapies, but price tags are looking rich.